The First Structure of Human MTHFD2L and Its Implications for the Development of Isoform-Selective Inhibitors.

"the coordinates and structure factors for hmthfd2l were deposited in the pdb under the accession code 7qei mthfd2l activity was monitored using the nad(p) glo(tm) detection system (promega)."

"Conflict of interest Thomas Helleday, Martin Henriksson, Evert Homan and Pål Stenmark are named inventors on patent application PCT/EP2019/059919. MTHFD2 inhibitors are developed toward the clinic by the company One‐Carbon Therapeutics AB, currently owned by The Helleday Foundation (THF), a not‐for‐profit charitable foundation. Thomas Helleday is a board member of THF. The remaining authors declare no competing interests."

"We thank the scientists at PXIII of the Swiss Light Source (Switzerland) for their support during data collection. This work has received funding from the Swedish Children's Cancer Foundation (PR2018‐0095 to T.H.), the Swedish Research Council (2015‐00162, 2017‐06095 to T.H. and 2018‐03406 to P.S.), the Swedish Cancer Society (CAN 2018/600 to T.H. and 201287 PjF to P.S.), the Swedish Pain Relief Foundation (T.H.) and the Torsten and Ragnar Söderberg Foundation (T.H.)."